External validation of the graded prognostic assessment for patients with non-small cell lung cancer and brain metastases using molecular markers (Lung-molGPA)
Radiation Oncology Journal · 31.03.2026 · 44 (1) · 1-7
DOI: 10.3857/roj.2024.00192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 31.03.2026. Verfasst von Soon Woo Hong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Purpose
Patients with non–small cell lung cancer (NSCLC) and brain metastases (BM) represent a markedly heterogeneous population. The diagnosis-specific graded prognostic assessment is one of the prognostic indexes, which includes patient age, performance status, extracranial disease, and number of BM. As an updated prognostic model (lung molecular graded prognostic assessment [Lung-molGPA]) with the incorporation of the molecular factor (epidermal growth factor receptor [EGFR] and anaplastic lymphoma kinase [ALK] alterations) was introduced, this study aims to validate the Lung-molGPA model in Korean patient population.Materials and Methods: Four hundred thirty-three patients (368 adenocarcinoma and 65 nonadenocarcinoma) with NSCLC with newly diagnosed BM between 2005 and 2017 were reviewed retrospectively and scored using the Lung-molGPA model.
Results
The overall median survival for the cohort in the present study was 14 months (16.5 months in the adenocarcinoma and 8.0 months in the nonadenocarcinoma, respectively; p = 0.003). For patients with adenocarcinoma, the median survival for patients with a Lung-molGPA score of 3.5 to 4.0 was 44.7 months, while the median survival was only 8.9 months in patients scoring 0-1.0, 17.0 months in patients scoring 1.5–2.0, and 30.2 months for scores of 2.5–3.0 (p < 0.001). For patients with nonadenocarcinoma, the median survival for scores 0–1.0, 1.5–2.0, and 2.5–3.0 were 6.7, 10.3, and 13.2 months, respectively (p = 0.041).
Conclusion
Notable prognostic factors for patients with NSCLC and BM include the patient’s age, performance status, metastatic lesions, and the molecular status of the adenocarcinoma. Our independent validation in a single-institution Korean patient cohort confirmed the applicability of Lung-molGPA as a prognostic tool.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Science, Busan, Republic of Korea.
- Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Hong, S. W., Jeon, W., Kim, J. S., & Song, C. (2026). External validation of the graded prognostic assessment for patients with non-small cell lung cancer and brain metastases using molecular markers (Lung-molGPA). Radiation Oncology Journal, 44(1), 1-7. https://doi.org/10.3857/roj.2024.00192
Vancouver
Hong SW, Jeon W, Kim JS, Song C. External validation of the graded prognostic assessment for patients with non-small cell lung cancer and brain metastases using molecular markers (Lung-molGPA). Radiation Oncology Journal. 2026;44(1):1-7. doi:10.3857/roj.2024.00192
BibTeX
@article{Hong2026,
author = {Hong, Soon Woo and Jeon, Wan and Kim, Jae-Sung and Song, Changhoon},
title = {External validation of the graded prognostic assessment for patients with non-small cell lung cancer and brain metastases using molecular markers (Lung-molGPA)},
journal = {Radiation Oncology Journal},
year = {2026},
volume = {44},
number = {1},
pages = {1--7},
doi = {10.3857/roj.2024.00192}
}
EUVIMED